NO965520L - Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner - Google Patents

Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner

Info

Publication number
NO965520L
NO965520L NO965520A NO965520A NO965520L NO 965520 L NO965520 L NO 965520L NO 965520 A NO965520 A NO 965520A NO 965520 A NO965520 A NO 965520A NO 965520 L NO965520 L NO 965520L
Authority
NO
Norway
Prior art keywords
hydroxyalkylammonium
inhibitors
inflammatory cytokines
purines
pyrimidines
Prior art date
Application number
NO965520A
Other languages
English (en)
Other versions
NO965520D0 (no
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Lavandera Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Ronald J Uhing
Henry Wong
Original Assignee
Macronex Inc
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macronex Inc, Univ North Carolina filed Critical Macronex Inc
Publication of NO965520D0 publication Critical patent/NO965520D0/no
Publication of NO965520L publication Critical patent/NO965520L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nye hydroksyalkylammonium- pyrimidin- og nukleosidderivater (I) Hn I R R" R" (I) er blitt funnet å kunne anvendes som inhibitorer for inflammatoriske cyto- kiner. De kan blant annet anvendes ved behandlingen av septisk sjokk, kakeksi, reumatoid artritt, inflammatorisk tarm- sykdom, multippel sklerose og AIDS. Forbindelsene fremstilles vanligvis ved omsetning av et jodsubstituert nukleo- sid med det passende substituerte hydroksyalkylamin, hvor R er en gruppe med formel (a) / RjO - (CH2)n - N - (CH2)2 OCH, (a) hvor R^ er én eller to lavere alkyl- grupper, med det forbehold at når to lavere alkylgrupper er til stede, så er nitrogenatomet kvaternisert; R2 er hydrogen eller en alkanoylgruppe med 2-20 karbonatomer; n er 2-6; eller R er en substituert furanylgruppe med formel (b) Ri / - o. R:0 - (CHj)¿ - N-CH, vv^^ BO"^-- (b) hvor n, R^ og R2 er som definert tidligere; og bølgelinjene angir enten den ene eller andre stereokjemiske konfigurasjon; R' og R'' er uavhengig av hverandre hydrogen, halogen eller en lavere alkyl-, lavere alkenyl-, lavere alkynyl- eller aralkylgruppe; R''' er hydrogen, halogen, alkyltio, amino, acylamino, karbamyl eller azid; og de farmasøytisk akseptable salter der- av.
NO965520A 1994-06-22 1996-12-20 Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner NO965520L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,026 US5550132A (en) 1994-06-22 1994-06-22 Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
PCT/US1995/007896 WO1995035304A1 (en) 1994-06-22 1995-06-21 Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines

Publications (2)

Publication Number Publication Date
NO965520D0 NO965520D0 (no) 1996-12-20
NO965520L true NO965520L (no) 1997-02-21

Family

ID=23004241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965520A NO965520L (no) 1994-06-22 1996-12-20 Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner

Country Status (11)

Country Link
US (2) US5550132A (no)
EP (1) EP0766691B1 (no)
JP (1) JPH10509416A (no)
AT (1) ATE186545T1 (no)
AU (1) AU2906795A (no)
CA (1) CA2193645A1 (no)
DE (1) DE69513285D1 (no)
FI (1) FI965140A0 (no)
HU (1) HUT76332A (no)
NO (1) NO965520L (no)
WO (1) WO1995035304A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
DE19516247A1 (de) * 1995-05-03 1996-11-07 Albrecht Prof Dr Wendel Pyrogen-Untersuchungsverfahren
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
BR9610375A (pt) * 1995-09-07 1999-07-06 Oreal Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético
FR2746647B1 (fr) * 1996-03-27 1998-05-15 Oreal Composition apaisante comprenant un extrait d'iridacee
GB9615202D0 (en) * 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
ES2191462T3 (es) 1998-10-01 2003-09-01 Astrazeneca Ab Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
JP4619545B2 (ja) * 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US6280633B1 (en) 1999-12-01 2001-08-28 Fantom Technologies Inc. Ozone sensor and method for use of same in water purification system
WO2001072730A1 (fr) * 2000-03-28 2001-10-04 Michio Ishibashi Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe
AU7931301A (en) 2000-08-04 2002-02-18 Dmi Biosciences Inc Method of using diketopiperazines and composition containing them
AU2003279761B2 (en) * 2002-10-02 2009-11-12 Luoxis Diagnostics, Inc. Diagnosis and monitoring of diseases
ES2575563T3 (es) 2003-05-15 2016-06-29 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
US7745227B2 (en) * 2003-08-12 2010-06-29 Lawrence Livermore National Security, Llc System for analysis of explosives
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20060086388A1 (en) * 2004-10-27 2006-04-27 Blake Fye Venting device for degassing a flow of liquid in a closed system
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
PL2766029T3 (pl) 2011-10-10 2020-08-24 Ampio Pharmaceuticals, Inc. Leczenie choroby zwyrodnieniowej stawów
KR20140075772A (ko) 2011-10-10 2014-06-19 앰피오 파마슈티컬스 인코퍼레이티드 면역 내성을 증가시킨 이식 의료 장비, 및 그의 제조 및 이식 방법
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
KR20150132508A (ko) 2013-03-15 2015-11-25 앰피오 파마슈티컬스 인코퍼레이티드 줄기세포의 가동화, 회귀, 증식 및 분화를 위한 조성물 및 이의 사용 방법
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
JPS60181075A (ja) * 1984-02-28 1985-09-14 Shoichiro Ozaki ピリミジン類，その製法およびその利用法
DK163128C (da) * 1986-08-12 1992-06-15 Hoffmann La Roche Pyrimidinnucleosider, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende pyrimidinnucleosiderne og anvendelse af pyrimidinnucleosiderne
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
DE69223607T2 (de) * 1991-04-05 1998-07-02 Wisconsin Alumni Res Found Verwendung von Substanzen zur Verhütung von Endotoxinschock
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
EP0766691A1 (en) 1997-04-09
AU2906795A (en) 1996-01-15
US5550132A (en) 1996-08-27
FI965140A (fi) 1996-12-20
NO965520D0 (no) 1996-12-20
HU9603535D0 (en) 1997-02-28
US5679684A (en) 1997-10-21
CA2193645A1 (en) 1995-12-28
EP0766691B1 (en) 1999-11-10
JPH10509416A (ja) 1998-09-14
ATE186545T1 (de) 1999-11-15
DE69513285D1 (de) 1999-12-16
FI965140A0 (fi) 1996-12-20
WO1995035304A1 (en) 1995-12-28
HUT76332A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
NO965520D0 (no) Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner
NO965521D0 (no) N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
EA199801047A1 (ru) Замешенные призводные инлазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
DK0594636T3 (da) 3-aminopiperidinderivater og relaterede nitrogenholdige heterocykliske forbindelser
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
DK0749428T3 (da) Isooxazolinforbindelser som inhibitorer af TNF-frigivelse
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
NO922524D0 (no) Pyrimidinderivater, deres fremstilling og anvendelse
DK0619806T3 (da) Fremstilling af substituerede piperidiner
DE50209545D1 (de) Flüssigkristallines medium
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
ATE71368T1 (de) N-aryltetrahydrophthalimidderivate und deren vorprodukte.
MXPA04004010A (es) Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
FI971177A (fi) Bisyklisiä karboksiamideja 5-HT1A-antagonisteina
PT1294729E (pt) 2-aminoalquil-tieno[2,3-d]pirimidinas
AU1002983A (en) Substituted 1-benzoyl-2-phenyliminoimidazolines
IL72681A0 (en) 4-alkylimidazole derivatives,their preparation and their use as nitrification inhibitors
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
ATE37531T1 (de) Bestimmte 2-(2-substituierte benzoyl)-1,3cyclohexandione.
GR1002589B (el) Ενωσεις τριαρυλο ιμιδαζολης.
ITMI912078A1 (it) Procedimento per impiegare ceneri di carbone nella produzione di laterizi per murature.